We then examined the potential impact of molecular alterations in patients with liver metastasis specifically, and the presence of KRAS mutations significantly predicted worse overall survival with a hazard ratio of 2.01 (p < 0.001) (Table 4). The gene discussed is KRAS; the disease is metastasis.